8-K: Voyager Therapeutics CFO Resigns, Successor Appointed
Current Report (8-K)
Voyager Therapeutics announced the resignation of its Chief Financial Officer, Nathan Jorgensen, effective May 8, 2026, and the appointment of Robin Swartz as principal financial officer and treasurer.
Summary
- Nathan Jorgensen, Ph.D., is resigning as Chief Financial Officer of Voyager Therapeutics, Inc. effective May 8, 2026, to pursue a new opportunity.
- Dr. Jorgensen's resignation is not due to any disagreement with the Company.
- Robin Swartz has been appointed as the principal financial officer and treasurer, effective May 8, 2026.
- Amy Quinlan has been appointed as the principal accounting officer, effective May 8, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While executive changes can introduce uncertainty, the smooth nature of the transition and the experienced internal appointments mitigate significant negative sentiment.
Positives
- The departure of the CFO is not a result of any disagreement with the Company, indicating a smooth transition.
- Robin Swartz, the appointed principal financial officer and treasurer, has extensive experience within the company and prior roles at Genzyme and Sanofi Genzyme, including finance operations, internal auditing, and financial planning and analysis.
- Amy Quinlan, the appointed principal accounting officer, has relevant experience as Vice President of Finance at Vor Biopharma Inc. and in various roles at Tetraphase Pharmaceuticals, Inc.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it solely pertains to executive changes.
Industry Context
StockSavvy.ai notes that executive transitions, particularly for key financial roles, are common in the biotechnology sector as companies evolve. The appointment of internal candidates with extensive financial and operational backgrounds, like Robin Swartz, can signal a focus on continuity and leveraging existing institutional knowledge.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Nathan Jorgensen, Ph.D. | 2026-05-08 | To pursue a new opportunity | |
| Principal Financial Officer and Treasurer | Robin Swartz | 2026-05-08 | In connection with the transition of Dr. Jorgensen | |
| Principal Accounting Officer | Amy Quinlan | 2026-05-08 | In connection with the transition of Dr. Jorgensen |
Stakeholder Impact
- Shareholders: The change in CFO may lead to a period of adjustment, but the appointment of an experienced internal candidate is generally viewed positively for continuity.
- Employees: The transition of key financial leadership may create some uncertainty, but the established experience of the new appointees should provide reassurance.
- Creditors: The financial stability and reporting integrity are maintained with experienced individuals stepping into critical roles.
Key Dates
| Date | Description |
|---|---|
| 2026-04-15 | Date of Report (Date of Earliest Event Reported) |
| 2026-04-15 | Nathan Jorgensen notified the Company of his decision to resign as Chief Financial Officer. |
| 2026-04-20 | Board of Directors appointed Robin Swartz and Amy Quinlan. |
| 2026-05-08 | Effective date of Dr. Jorgensen's transition and the effective date for the appointments of Ms. Swartz and Ms. Quinlan. |
| 2026-10-28 | Date of filing of Exhibit 10.10 to the Company's Registration Statement on Form S-1 (related to indemnification agreement for Ms. Quinlan). |
Keywords
Voyager Therapeutics, CFO Resignation, Chief Financial Officer, Robin Swartz, Amy Quinlan, Principal Financial Officer, Principal Accounting Officer, Executive Appointment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.